{"title":"坦桑尼亚多多马本杰明-姆卡帕地区转诊医院的抗菌药消耗趋势和模式:横断面回顾性分析。","authors":"Kauke Bakari Zimbwe, Yusto Julius Yona, Charity Alphonce Chiwambo, Alphonce Bilola Chandika, Humphrey Sawira Kiwelu, Moshi Moshi Shabani","doi":"10.1136/bmjopen-2023-083842","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This study assessed the trends and patterns of antimicrobial consumption (AMC) from 2020 to 2021, 2021-2022 and 2022-2023 at the Benjamin Mkapa Zonal Referral Hospital (BMH) in Dodoma, Tanzania.</p><p><strong>Design: </strong>A retrospective cross-sectional study was conducted to collect AMC data for three financial years with respective denominators. The data were computed using the AMC Tool 2019 v1.9.0 and defined daily dose per 1000 inhabitants per day (DID).</p><p><strong>Setting: </strong>The BMH, Dodoma, Tanzania.</p><p><strong>Participants: </strong>This study surveyed quantities of antimicrobials procured at the BMH. It did not have any human participants.</p><p><strong>Outcome measures: </strong>AMC was quantified in DID. The comparisons were made based on the DID of all surveyed antimicrobials, taking into account oral and parenteral administration and based on pharmacological classes. Further, DIDs were presented based on the 2023 WHO Access (A), Watch (W) and Reserve (R) (AWaRe) classification.</p><p><strong>Results: </strong>In 29 assessed antimicrobials, the DIDs for 2020-2021, 2021-2022 and 2022-2023 were 3.0852, 3.5892 and 3.9213, respectively. The average DID per year was 3.5319, with a mean of 2.4207±1.9765 DID per year. The topmost consumed antimicrobials over the 3 years (doxycycline, azithromycin, amoxicillin/beta-lactamase inhibitors, ampicillin/cloxacillin, amoxicillin/flucloxacillin, ceftriaxone, nitrofurantoin and clarithromycin) account over 90% of consumption. The most highly consumed therapeutic classes were beta-lactam antibacterial penicillins (34.71%), macrolides, lincosamides, streptogramins and others (25.75%), followed by tetracycline (23.88%). The AWaRe categorisation and antimicrobials not recommended (ANR) distribution were as follows: Access-51.61%, Watch-31.96%, Reserve-0.00%, and ANR-16.43%, respectively.</p><p><strong>Conclusion: </strong>For every 1000 patients attending the BMH per day, our study found 2.4207±1.9765 DIDs of an antimicrobial were consumed. The most consumed antimicrobials include doxycycline, azithromycin, amoxicillin/beta-lactamase inhibitor, ceftriaxone and metronidazole. To combat antimicrobial resistance effectively, it is imperative to institute a hospital policy for antimicrobial stewardship that prioritises the utilisation of a hospital formulary and antibiograms for the procurement of antimicrobials at the BMH.</p>","PeriodicalId":9158,"journal":{"name":"BMJ Open","volume":null,"pages":null},"PeriodicalIF":2.4000,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Trends and patterns of antimicrobial consumption at Benjamin Mkapa Zonal Referral Hospital, Dodoma, Tanzania: a cross-sectional retrospective analysis.\",\"authors\":\"Kauke Bakari Zimbwe, Yusto Julius Yona, Charity Alphonce Chiwambo, Alphonce Bilola Chandika, Humphrey Sawira Kiwelu, Moshi Moshi Shabani\",\"doi\":\"10.1136/bmjopen-2023-083842\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>This study assessed the trends and patterns of antimicrobial consumption (AMC) from 2020 to 2021, 2021-2022 and 2022-2023 at the Benjamin Mkapa Zonal Referral Hospital (BMH) in Dodoma, Tanzania.</p><p><strong>Design: </strong>A retrospective cross-sectional study was conducted to collect AMC data for three financial years with respective denominators. The data were computed using the AMC Tool 2019 v1.9.0 and defined daily dose per 1000 inhabitants per day (DID).</p><p><strong>Setting: </strong>The BMH, Dodoma, Tanzania.</p><p><strong>Participants: </strong>This study surveyed quantities of antimicrobials procured at the BMH. It did not have any human participants.</p><p><strong>Outcome measures: </strong>AMC was quantified in DID. The comparisons were made based on the DID of all surveyed antimicrobials, taking into account oral and parenteral administration and based on pharmacological classes. Further, DIDs were presented based on the 2023 WHO Access (A), Watch (W) and Reserve (R) (AWaRe) classification.</p><p><strong>Results: </strong>In 29 assessed antimicrobials, the DIDs for 2020-2021, 2021-2022 and 2022-2023 were 3.0852, 3.5892 and 3.9213, respectively. The average DID per year was 3.5319, with a mean of 2.4207±1.9765 DID per year. The topmost consumed antimicrobials over the 3 years (doxycycline, azithromycin, amoxicillin/beta-lactamase inhibitors, ampicillin/cloxacillin, amoxicillin/flucloxacillin, ceftriaxone, nitrofurantoin and clarithromycin) account over 90% of consumption. The most highly consumed therapeutic classes were beta-lactam antibacterial penicillins (34.71%), macrolides, lincosamides, streptogramins and others (25.75%), followed by tetracycline (23.88%). The AWaRe categorisation and antimicrobials not recommended (ANR) distribution were as follows: Access-51.61%, Watch-31.96%, Reserve-0.00%, and ANR-16.43%, respectively.</p><p><strong>Conclusion: </strong>For every 1000 patients attending the BMH per day, our study found 2.4207±1.9765 DIDs of an antimicrobial were consumed. The most consumed antimicrobials include doxycycline, azithromycin, amoxicillin/beta-lactamase inhibitor, ceftriaxone and metronidazole. To combat antimicrobial resistance effectively, it is imperative to institute a hospital policy for antimicrobial stewardship that prioritises the utilisation of a hospital formulary and antibiograms for the procurement of antimicrobials at the BMH.</p>\",\"PeriodicalId\":9158,\"journal\":{\"name\":\"BMJ Open\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2024-11-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMJ Open\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1136/bmjopen-2023-083842\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMJ Open","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/bmjopen-2023-083842","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
摘要
研究目的本研究评估了坦桑尼亚多多马本杰明-姆卡帕地区转诊医院(BMH)2020-2021年、2021-2022年和2022-2023年抗菌药物消耗量(AMC)的趋势和模式:进行了一项回顾性横断面研究,收集了三个财政年度的AMC数据,并分别列出了分母。数据使用AMC工具2019 v1.9.0计算,并定义了每1000名居民每天的日剂量(DID):坦桑尼亚多多马的 BMH:本研究调查了 BMH 采购抗菌药物的数量。结果测量:AMC以DID量化。根据所有调查抗菌药物的 DID 进行比较,同时考虑到口服和肠外给药以及药理类别。此外,还根据 2023 年世界卫生组织的准入(A)、观察(W)和储备(R)(AWaRe)分类法列出了 DID:结果:在 29 种接受评估的抗菌药物中,2020-2021 年、2021-2022 年和 2022-2023 年的 DID 分别为 3.0852、3.5892 和 3.9213。平均每年 DID 为 3.5319,平均每年 DID 为 2.4207±1.9765。三年中消费量最大的抗菌药物(强力霉素、阿奇霉素、阿莫西林/β-内酰胺酶抑制剂、氨苄西林/环丙西林、阿莫西林/氟氯西林、头孢曲松、硝基呋喃妥因和克拉霉素)占消费量的 90%以上。消耗量最大的治疗类药物是β-内酰胺类抗菌青霉素(34.71%)、大环内酯类、林可酰胺类、链霉素及其他(25.75%),其次是四环素(23.88%)。AWaRe分类和不推荐使用的抗菌药物(ANR)分布情况如下:获得-51.61%,观察-31.96%,保留-0.00%,不推荐-16.43%:我们的研究发现,每天每 1000 名在 BMH 就诊的患者中,就有 2.4207±1.9765 DIDs 的抗菌药物被消耗。消耗最多的抗菌药物包括强力霉素、阿奇霉素、阿莫西林/β-内酰胺酶抑制剂、头孢曲松和甲硝唑。为了有效对抗抗菌素耐药性,必须制定医院抗菌素管理政策,优先使用医院处方集和抗生素图谱来采购抗菌素。
Trends and patterns of antimicrobial consumption at Benjamin Mkapa Zonal Referral Hospital, Dodoma, Tanzania: a cross-sectional retrospective analysis.
Objective: This study assessed the trends and patterns of antimicrobial consumption (AMC) from 2020 to 2021, 2021-2022 and 2022-2023 at the Benjamin Mkapa Zonal Referral Hospital (BMH) in Dodoma, Tanzania.
Design: A retrospective cross-sectional study was conducted to collect AMC data for three financial years with respective denominators. The data were computed using the AMC Tool 2019 v1.9.0 and defined daily dose per 1000 inhabitants per day (DID).
Setting: The BMH, Dodoma, Tanzania.
Participants: This study surveyed quantities of antimicrobials procured at the BMH. It did not have any human participants.
Outcome measures: AMC was quantified in DID. The comparisons were made based on the DID of all surveyed antimicrobials, taking into account oral and parenteral administration and based on pharmacological classes. Further, DIDs were presented based on the 2023 WHO Access (A), Watch (W) and Reserve (R) (AWaRe) classification.
Results: In 29 assessed antimicrobials, the DIDs for 2020-2021, 2021-2022 and 2022-2023 were 3.0852, 3.5892 and 3.9213, respectively. The average DID per year was 3.5319, with a mean of 2.4207±1.9765 DID per year. The topmost consumed antimicrobials over the 3 years (doxycycline, azithromycin, amoxicillin/beta-lactamase inhibitors, ampicillin/cloxacillin, amoxicillin/flucloxacillin, ceftriaxone, nitrofurantoin and clarithromycin) account over 90% of consumption. The most highly consumed therapeutic classes were beta-lactam antibacterial penicillins (34.71%), macrolides, lincosamides, streptogramins and others (25.75%), followed by tetracycline (23.88%). The AWaRe categorisation and antimicrobials not recommended (ANR) distribution were as follows: Access-51.61%, Watch-31.96%, Reserve-0.00%, and ANR-16.43%, respectively.
Conclusion: For every 1000 patients attending the BMH per day, our study found 2.4207±1.9765 DIDs of an antimicrobial were consumed. The most consumed antimicrobials include doxycycline, azithromycin, amoxicillin/beta-lactamase inhibitor, ceftriaxone and metronidazole. To combat antimicrobial resistance effectively, it is imperative to institute a hospital policy for antimicrobial stewardship that prioritises the utilisation of a hospital formulary and antibiograms for the procurement of antimicrobials at the BMH.
期刊介绍:
BMJ Open is an online, open access journal, dedicated to publishing medical research from all disciplines and therapeutic areas. The journal publishes all research study types, from study protocols to phase I trials to meta-analyses, including small or specialist studies. Publishing procedures are built around fully open peer review and continuous publication, publishing research online as soon as the article is ready.